Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A

The clinical hold was initiated following the Companys submission of a serious adverse event (SAE) and temporary enrollment halt to the FDA and other regulatory agencies.